Objective: To evaluate the role of specific macrophage subpopulations in the development of zymosaninduced multiple-organ dysfunction syndrome by selec tive elimination of liver, splenic, alveolar, and perito neal macrophages.
N NORMAL host-defense media-macrophages that could induce a generalnisms, an inflammatory response ized dysregulated excessive inflammatory reis ideologically beneficial and is meant to protect the host against injurious events. n ; con-sponse, leading to the development of SIRS, ARDS, or MODS.4'6 This hypothesis is sup ported by various observations. First, adtrary, in pathological conditions (eg, the sys-ministration of macrophage-derived cytotemic inflammatory response syndrome kines to healthy volunteers produces a [SIRS], the adult respiratory distress syn drome [ARDS] , and the multiple-organ dys function syndrome [MODS] ), an exces sive generalized inflammatory response may
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have detrimental effects on the host. 12 Mac-syndrome that closely resembles SIRS experimental macro development rophages play a pivotal role in normal hostdefense mechanisms because of their anti microbial phagocytic activity, antigenpresenting capacity, and regulation of the inflammatory response by their secretion of various imimmoregulatory substances. 5 However, evidence has been accumulating terleukin-1,, and neopterin) with a positive with regard to an excessive activation of correlation of elevated levels with the sub-ARDS, and MODS, as demonstrated by in creased levels of macrophage-derived prod ucts (eg, tumor necrosis factor [TNF], in-
MATERIALS AND METHODS
86 mg of phosphatidylcholine (Lipoicl GmbH, Ludwigshafen, Germany) and 8 mg of cholesterol (Sigma Chemi-ANIMALS ca* were dissolved in 10 mL of chloroform, and a lipid film was produced by low-vacuum rotaiy evaporation. Sub-Inbred, specific pathogen-free, male C57B1/6 mice (Charles sequently, 10 mL of the C12MBP solution was added, and Rivers, Wiga, Germany) (age range, 6-8 weeks) were adapted to handling in their cages for 7 days prior to the start of the the suspension was left at room temperature for 2 hours, sonicated for 3 minutes at 20°C, and left for 2 hours at 37°C. actual experiment. Throughout the experiment, all mice had
The liposome suspension was then diluted in 100 mL of free access to water that was acidified with hydrochloric acid PBS, centrifuged at 100 OOOg for 30 minutes to remove free (to pH 3) and to standard mice laboratory chow (RMH-GS pellets [irradiated at 10 kGy], Hope Farms, Woerden, the Netherlands). The room temperature was kept constant at 21°C, and a 12-liour lighting cycle was maintained. The ex periments were approved by the Animal Ethics Committee of the Medical Faculty of the University of Nijmegen, Nij megen, the Netherlands. C12MBP, and resuspended in 4 mL of PBS.
ELIMINATION OF MACROPHAGE SUBPOPULATIONS ZYMOSAN
Elimination of Kupffer cells and splenic macrophages was achieved by an intravenous (IV) injection of 200 |xL of li posomes that contained C12MBP in the tail vein; this method has been demonstrated previously to achieve an elimina tion of these macrophages within 2 days.22 Alveolar mac-ZymosanA (Sigma Chemical Co, St Louis, Mo), sterilized by rophages were eliminated by adm inistering Cl2MBP~ use of 7-irradiation (5 kGy), was suspended (25 mg/mL) by containing liposomes intratracheally (IT).27 The mice were high-frequency vibration in liquid paraffin (60-80 mPa, Eu ropean Pharmacopoeia PA.S.68.81 CP846021). The suspen sion was sterilized by incubation in a water bath at 100° C for 80 minutes. One day before use, the suspension was heated hydrochloride (Rompun, Bayer, Leverkusen, Germany), and fixed in an upright position under total anesthesia with 30 |xL of a mixture (ratio, 4:3:7) of ketamine hydrochloride (100 mg/mL) (A.U.V., Cuijk, the Netherlands), xylazine to 40°C and dispersed by high-frequency vibration for 15 min utes. Sterility was confirmed by culture on a blood agar me dium. The zymosan suspension was administered IP in a dose of 1 mg/g of body weight.
saline that was injected intramuscularly. Using a nylon tube (diameter, 0.46 mm) that was connected to a 1-mL sy ringe fixed in a micromanipulator, 100 |xL of the C12MBPcontaining liposome suspension was administered through the glottis into the trachea. It has been demonstrated by this method that alveolar, but not interstitial, m acro phages are eliminated within 3 to 5 hours.27 Elimination of peritoneal macrophages was accomplished by adminis-Multilamellar liposomes were composed of phosphatidyl-tering 100 |xL of Cl2MBP-containing liposomes IP, 2 times choline and cholesterol (molar ratio, 6:1) and contained successively. '13 Several studies have been ascribed a special patho physiological role to specific macrophage subpopula tions (eg, alveolar macrophages,14,15 Kupffer cells,16,17 splenic macrophages,18,19 and peritoneal m acro phages20,21) in these syndromes.
An alternative approach to study the respective causal role of macrophage subpopulations in the pathogenesis of MODS is by investigating the effects of selective elimi nation of these cells. For this purpose, we used the "li posome-mediated macrophage suicide technique."22 In this approach, dichloromethylene bisphosphonate (C12MBP or clodronate) is selectively delivered intracellularly to macrophages by a liposome carrier; this re sults in a destruction of the cell. Other cells are not struc turally or functionally affected by this technique.23 By varying the route of administra tion, liposomes can be tar geted to eliminate macrophages in specific tissues. 22 We have applied this technique in the zymosaninducecl generalized inflammation model. In rodents, intraperitoneal (IP) challenge with zymosan, a particulate cell wall product of the yeast Sa.ccha.romy ces cerevisiae, in duces a typical triphasic illness with an early hyperdynamic response with concurrent bacterial translocation from the gut and, after a recovery phase, a late bacteria-independent hypodynamic MODS-like phase with a generalized inflam matory response and organ dysfunction.24,25
Recently, we have shown that elimination of liver and splenic macrophages can abrogate the early hyper dynamic response in this model, despite an increased bac terial translocation.26 The purpose of the present study is to determine the role of specific macrophage subpopu lations (ie, liver, spleen, alveolar, or peritoneal m acro phages) in the development of MODS by studying the consequences of selective elimination of those m acro phage subpopulations, either prior to or after the chal lenge with zymosan, for the clinical syndrome and or gan damage in the late phase of this model.
RESULTS
Elimination of liver and splenic macrophages was con firmed by the absence of acid phosphatase activity of liver and splenic tissue ( Figure 1 ) in the mice that were treated. ARCH SURG/VQL 132, MAY 1997 I'Oi each route ol liposome administration, verifica-groups received liposomes either 2 days before or 4 days tion of macrophage elimination was performed on 3 ani-after zymosan challenge. The effects of IT liposome ads were compared with those for un-ministration were studied, in 3 groups of 20 mice each. The treated mice. Elimination of macrophages in the liver and experimental groups received liposomes either 3 days bespleen was verified by analyzing acid phosphatase activity fore or 4 days after zymosan challenge. Three groups of simiin 8-(xm cryostat tissue sections of liver and spleen 2 days lar size were used to examine the effects of IP liposome adafter IV injection of CljMBP-containing liposomes. Acid ministration, for which the experimental groups received phosphatase activity was demonstrated by incubation with liposomes either both 4 days and 1 day before or 1 day and 1% naphthol-AS-BI-phosphate and 4% hexazotized para-4 days after zymosan challenge. rosaniline for 30 minutes at 37°C. Elimination of alveolar In all mice, body weight and rectal temperature were macrophages was verified by quantification of macro-measured daily. The clinical condition with possible sympphages in the alveolar lavage fluid at 2 days after IT ad-toms such as loss of hemorrhagic fluid from the nose, conniinistration of Cl MBP-containing liposomes. After the junctiva, and mouth, lethargy, anorexia, hyperventilalungs were dissected free, alveolar lavage was performed 3 tion, ruffled fur and loss of liquid stools, and mortality rate times with 1 mL of PBS that contained 0.38% citrate. After were monitored. On day 12, all surviving mice were bled staining with trypan blue, cells were counted using a he-and killed by cervical dislocation; the lungs with the tramocytome ter chamber (Burker counter, Tamson Co, Zoe-chea, kidneys, liver, and spleen were dissected free and termcer, the Netherlands). Cytospin preparations con-weighed. Relative organ weights (ROWs) were calculated firmed that more than 95% of the alveolar cells were by the following formula: ROW= (organ weight/body macrophages. Elimination of the peritoneal macrophages weight) X100%. was verified by quantification of macrophages in the peri toneal lavage fluid. The liposomes that contained C12MBP STATISTICAL ANALYSIS were administered IP at days -4 and -1. At day 0, peri toneal lavage was performed with 4 mL of PBS that con-Comparisons were only made between treatment groups tained 0.38% citrate. Quantification of cells was per-and their specific control groups. Statistical analysis of bioformed as described previously.
EXPERIMENTAL DESIGN
Three series of experiments were performed to assess the effects of macrophage elimination in the various tissues. Within each series, 3 groups of mice were used: a control group that received only zymosan and 2 experimental groups that received the Cl2MBP-containing liposome suspen sion either before or after administration of zymosan.
Thus, 3 groups of 15 animals were used to study the effects of IV liposome administration. The experimental logical parameters (body temperature and body weight) was performed using the distribution-free curve analysis ac cording to Koziol et al. 29 Since the zymosan-induced ill ness is characterized by distinct phases, comparisons were made separately for the course of the biological param eters in die acute phase (days 0-4) and late phase (days 8-12) of the model. The nonparametric Kruskal-Wallis and Wilcoxon 2-sample tests were used for statistical analysis of the ROWs. Noncontinuous data (mortality rates) were ana lyzed by use of the Fisher exact or x 2 tests, when appro priate. Differences between groups were considered to be statistically significant at P<.05.
IV with CliMBP-containing liposomes. Reduction of al-lethargic and hypotherm ic, hyperventilated, an d started veolar and peritoneal macrophages was confirmed by to lose weight and hemorrhagic fluid from the nostrils a n d quantification of the macrophage cell concentration in conjunctivae again. The mortality of the control anim als the alveolar and peritoneal lavage fluid, respectively. Mice varied among the 3 experiments, w ith overall survival rates that were treated IT with Cl2MBP-containing liposomes of 47%, 75%, and 50% in the control mice w ith IV, IT, a n d strated a m ean m acrophage concentration of 6. Elimination ofliver and splenic m acrophages by IV adm inistration of Cl2M BP-containing liposom es before or after challenge w ith zymosan did n o t in d u ce signifi-0-4), the animals became hypothermic, lethargic, and ano-cant changes in the subsequent course of body w eig h t rectic; they hyperventilated, lost weight and hem or-and temperature (data not shown). No significant changes rhagic fluid from the nostrils and conjunctivae, and had were observed in the m ortality betw een the control a n d diarrhea. Thereafter, the condition of the surviving ani-Cl2MBP-containing liposom e-treated groups: overall su r-
mals improved temporarily. However, after 8 days, the clini cal condition worsened progressively. In this late hypo vival rates were 47% in the control m ice an d 60% ancl 53% w hen mice were treated w ith liposom es before or dynamic phase (days 8-1,2), the animals became more after zymosan challenge, respectively (Figure 2) . In tra -ARCH SURG/VOL 132, MAY 1997 due to the fact that the animals died in the early phase of With no reliable conclusions could be made with respect to or gan damage. In the animals that were treated with liposomes alter zymosan vnge, no statistici ROWs This study shows that elimination of Kupffer cells and splenic macrophages (portal macrophages), either before or after zymosan challenge, is associated with lower, al though not significantly, late deaths and significantly lower relative liver weights, indicating less liver damage. This is consistent with studies that have documented that excessive Kupffer cell activation is associated in liver function.16 Concomitantly, relative ter zymosan chi plained in view of other studies that have that ARDS and MODS Kupffer cells, which spill over endotoxin to induce an excessive activation of alveolar macr L'cause venous administration ofliposomes after zymosan chal lenge led to significantly increased relative lung weights, while relative liver weights were significantly reduced in both groups that were tested with liposomes ( Figure 3 ). No significant differences were noticed in relative spleen and kidney weights.
Intratracheal administration ofliposomes that con tained C12MBP before or after zymosan challenge did not result in significant differences in the course of the bio logical parameters (data not shown). While 25% of the animals died in the control group, no deaths occurred in the group that received liposomes before zymosan rimental in models or clinical situations that depend on this phenomenon has been coined the "liver-lung axis." Indeed, alveolar macrophages are releasing much more TNF in response to lipopolysaccharicle than Kupffer cells.50 Thus, by this mechanism, elimination of portal macro phages could lead to an activation of alveolar macro phages that results in increased lung damage. Our data did not show adverse effects on the m or tality rate by eliminating portal macrophages. This is in contrast with a study in the cecal ligation and puncture model, in which Kupffer cell blockade was achieved with gadolinium chloride.31 While increasing systemic im m u nity, this method of macrophage blockade increased the mortality rate. These discordant results could be exinium blocks phagocytic activity of Kupffer cells, leaving mac rophage secretory activity relatively intact.52 The method, we cells, leaving no function intact.n Furthermore, while the zymosan-incluced generalized inflammation (ZIGI) model is largely independent of bacteria, the cecal ligation and puncture in which an intact host defense against bacteria is prob ably important.24,34 Apparently, the effects of m anipulat ing macr (P=.04), but elimination of alveolar macrophages after zymosan challenge did not significantly reduce the mor tality rate (Figure 2 ). Organ damage, as measured by the ROWs, was not significantly changed by elimination of alveolar macrophages (Figure 3 ).
Intraperitoneal administration of liposomes that con tained C12MBP did not significantly change the course of phages is essential for the host defense against intruding the intact phagocytic activity of the host defense. In this respect, our data of elimination of peritoneal macrophages are illustrative. Elimination of peritoneal mac rophages before zymosan challenge induced a dramatic inarly crease m rate, suggesting that m phase of this model, the function of peritoneal macro body weight and temperature (data not shown). How ever, administration of Cl2MBP-containing liposomes be fore zymosan challenge induced a dramatic mortality rate. While mortality was approximately 50% in the control group and the group that received liposomes after zymo san, it reached 90% if animals were pretreated with lipo somes (Figure 2 ; P=.02). The latter mortality was mainly microorganisms or injurious agents like zymosan. How ever, elimination of peritoneal macrophages after zymo san challenge did not induce such effects since the m or tality rate and ROWs were not significantly different. So, there appears to be a differential involvement of perito neal macrophages in the development of MODS in t his model: a protective role in the early phase and an indif- ARCH SlIRG/VOL 132, MAY 1997 537 nation of alveolar macrophages before zymosan chal lenge completely prevented mortality. This observation was consistently found in several pilot experiments (data not shown). This is in line with clinical data that have shown elevated levels of macrophage-derived cytokines (eg, TNF and interleukin-1) in bronchoalveolar lavage fluids in criti cally ill patients in whom ARDS develops.15 However, late elimination of alveolar macrophages did not alter the clini cal course or mortality rate, nor did it influence organ dam age. Thus, it appears that early alveolar activation is asso ciated w ith m ortality, w hile MODS ap p ears to be independent of late alveolar macrophage activation. Other investigators, however, have shown experimentally that lung injury in the cecal ligation and puncture model was associated w ith a gradual increase in alveolar m acro phage activation.14 Evidence for a less important role of the activated alveolar macrophage in the evolution of ARDS is supported by the clinical observation that early ARDS was associated w ith an increased num ber of m acro phages, while a sustained elevated num ber of m acro phages correlated with a decreased risk of death.38 These data suggest that early alveolar macrophage activation is associated with the onset of ARDS, while late alveolar mac rophage activation is associated with a resolution of ARDS.
A major finding of this study was that selective elimi nation of any macrophage subpopulation, either before or after zymosan challenge, could not prevent both organ dam age and death in this model. This could be explained by several hypotheses. First, during the development of MODS in this model, repopulation of some macrophages could al ready have been achieved in the late phase. Repopulation from the bone marrow requires 7 days for Kupffer cells and, depending on the type of macrophage, 7 days (red pulp mac rophages) to 60 days (marginal zone macrophages) for splenic macrophages.22 Alveolar macrophage repopula tion starts after 5 days and is complete after 18 days.27 Re population of peritoneal macrophages takes 7 days, and re population of macrophages of the omentum takes 7 to 28 days.28 W hen those macrophages were eliminated before zymosan challenge, their reappearance would be almost complete in the late phase, while it would be only partial when those macrophages were eliminated after the zymo san challenge.22 Hence, the reappearance of those macro phages in this phase could trigger the development of MODS if the agents or events that keep the macrophages acti vated are still present. Second, there are also indications in other models that the nondepleted macrophages dem onstrate an increased activity.22 Thus, the elimination of 1 subpopulation of macrophages could result in a compen satory activation of other macrophages or cell popula tions with an enhancement of the inflammatory response. In this respect, the observed increased lung organ damage after elimination of portal macrophages is an interesting phenomenon. Furthermore, elimination of peritoneal and alveolar macrophage populations was not complete; thus, the remaining macrophages could have hypothetically in duced MODS in this model. On the other hand, the dra matic effects of intra-alveolar and IP liposomes before zy mosan challenge suggest a significant contribution of the depletion of those macrophages to these phenomena.
The results could also be interpreted to support the notion that macrophage activation is not an im portant feature in the developm ent of MODS. Indeed, the m ac rophage hypothesis has been questioned because o f re cent clinical data, indicating th at preventive e n h a n c e m e n t o f m a c ro p h a g e a c tiv ity b y p o ly g lu c o tr io s y l glucopyranose glucan is beneficial for patien ts w h o are undergoing m ajor surgery or m ultiple trau m a.39,40 O n the other hand, our data indicate that elim ination of K upffer cells and splenic m acrophages attenuates liver dam age. he MODS that progresses to multiple-organ failure is a serious problem for patients who undergo surgical proce dures. Once multiple-organ failure develops, the mortality rate is high. Thus, information about the factors that are involved in producing this problem will eventually be beneficial for our patients. In this issue of the ARCHIVES, Nieuwenhuijzen and coworkers provide important information about macrophage activity in various organs (eg, the liver and spleen, the lungs [alveolar macrophages], and peritoneal cavity). Macrophages in these organs or locations were de stroyed by liposomes that contained a toxic agent, Then, the experimental animals were challenged by IP zymosan, which is an agent that produces a severe inflammatory reaction. Goris and colleagues1,1 have previously shown that zymosan-induced inflammation produces MODS or multiple-organ failure.
In the present study, elimination of alveolar macrophages prevented deaths caused by peritoneal inflammation, whereas elimination of peritoneal macrophages increased the zymosan-associated mortality rate. The elimination of Kupffer cells (from the liver) and splenic macrophages decreased liver damage, but increased lung damage. Thus, with zymosan-induced peri toneal inflammation, peritoneal macrophages are protective, whereas alveolar macrophages are deleterious. There were also time differences of early and late effects.
Thus, what is the message for all of us who take care of patients who undergo surgical procedures? The most important message is that the host-defense systems are complex, and they can be protective in some circumstances while deleterious in others. There will not be simple solutions to such problems clinically. It is unlikely that there will be a magic bullet. All so-called magic bullets that have been subjected to randomized, prospective clinical trials have failed to reduce the mortality rate in patients. These agents include interleukin-1 receptor antagonist antiendotoxins, anti-IN F antibodies, soluble TNF receptors, anti-platelet activating factor, and other agents. Thus, we must strive to prevent MODS ure by excellent patient care-operations without complications, minimal surgical procedures when possible, and maxi mum organ support. The more we learn from studies such as the one by Nieuwenhuijzen and coworkers and those et al1,2 commented on here, the more likely it is that we will be able to do something about overwhelming inflammation. Inflammation is necessary to heal wounds, control infection, and promote survival. Also, as Goris et al1,2 have described previously, overwhelming inflammation in patients is deleterious. The final question is: Can we fool Mother Nature and modulate a necessary but excessive response, namely, inflammation?
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